| Category | Candidate | Target | Indication | Preclinical | IND | Phase I | Phase II | Registration Trial | Application | Progress* and Upcoming Milestone | Partner |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology and autoimmune diseases | MIL62 | Third-generation CD20 (ADCC-enhanced) |
Follicular lymphoma(FL) Relapsed/refractory |
Phase III registration trial (recruiting patients) To submit NDA in 2024 2H |
|||||||
| Follicular lymphoma(FL) Untreated |
To submit Phase III registration trial application in 2021 2H |
||||||||||
| Diffuse large B-cell lymphoma(DLBCL) Relapsed/refractory |
Phase I/IIa trial (recruitment completed) Submitted Phase II registration trial application in July 2021To submit NDA in 2023 2H |
InnoCare | |||||||||
| Diffuse large B-cell lymphoma(DLBCL) Untreated |
To submit Phase II/III trial application in 2021 2H | InnoCare | |||||||||
| Lupus nephritis (LN) | Phase Ib/II trial (recruiting patients) | ||||||||||
| Primary membranous nephropathy (PMN) | Phase Ib/II trial (recruiting patients) | ||||||||||
| Neuromyelitis optical spectrum disorder (NMOSD) | IND application approved for Phase Ib/III trial | ||||||||||
| Myasthenia gravis (MG) | Submitted IND application in July 2021 | ||||||||||
| MIL93 | Claudin 18.2 (ADCC-enhanced) |
Claudin 18.2-positive gastric cancer, gastroesophageal junction cancer and pancreatic cancer | Phase I trial (recruiting patients) To submit Phase III registration trial application in 2023 1H |
||||||||
| MIL95 | CD47 | Lymphoma and advanced solid tumors | Phase I trial (recruiting patients) | Keymed | |||||||
| MIL97 | CD40 | Metastatic pancreatic cancer and other solid tumors | Submitted IND application in May 2021 Phase I trial (Australia) | ||||||||
| MBS301 | HER2/HER2 (ADCC-enhanced bispecific antibody) |
HER2-positive metastatic gastric cancer and other solid tumors | Phase I trial (recruiting patients) | ||||||||
| Others | MIL86 | PCSK9 | Hyperlipidemia | Phase II trial (recruiting patients) | |||||||
OncologyAutoimmune diseasesPlanned trial to be initiatedOthers
| Category | Candidate | Target | Indication | Preclinical | IND | Phase I | Phase II | Registration Trial | Application | Progress* and Upcoming Milestone | Partner |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncology and autoimmune diseases | MIL98 | LAG3 | Melanoma, late-stage lymphoma and other late-stage malignant solid tumors | To submit IND application in 2022 | |||||||
| MBS303 | CD3-CD20 | B cell non-Hodgkin lymphoma | To submit IND application in 2022 | ||||||||
| MBS304 | CD3/Claudin 18.2 | Gastric cancer and pancreatic cancer | To submit IND application in 2024 | ||||||||
| MBS307 | PD-L1/CD40 | Solid tumors | To submit IND application in 2023 | ||||||||
| MIL108 | B7-H3 (ADCC-enhanced) |
Non-small cell lung cancer and other solid tumors | To submit IND application in 2023 | Biocytogen | |||||||
| MBS309 | PD-1/IL-2 | Solid tumors | To submit IND application in 2024 | ||||||||
